加载中
NASDAQHealthcareBiotechnology
最新数据
US$75.81
+US$2.65 · +3.62%
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
常规交易时段
US$75.81
+US$2.65 · +3.62%
盘中时间采用ET。市场数据可能有所延迟。
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
日内区间
当前US$75.81
52周区间
当前US$75.81
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
82
深度低估
情绪
52
多空交织
风险
51
风险偏高
动量
40
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
日内区间
当前US$75.81
52周区间
当前US$75.81
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 4.51亿 USD | 1.83亿 USD | 1744.7万 USD | 2581.6万 USD | 5702.7万 USD |
| 销货成本 | 3068.4万 USD | 1282.6万 USD | 159.3万 USD | 95.5万 USD | 207.5万 USD |
| 毛利 | 4.21亿 USD | 1.7亿 USD | 1585.4万 USD | 2486.1万 USD | 5495.2万 USD |
| 研究与开发 | 6432.2万 USD | 5338.6万 USD | 5031.2万 USD | 4262.4万 USD | 4171.2万 USD |
| 销售、一般及管理费用 | 4.27亿 USD | 2.37亿 USD | 1.09亿 USD | 4494.9万 USD | 2539.7万 USD |
| 营业费用 | 4.92亿 USD | 2.91亿 USD | 1.59亿 USD | 8757.3万 USD | 6710.9万 USD |
| 利息收入 | 1574.7万 USD | 1501.4万 USD | 1033.7万 USD | 349.9万 USD | 3.6万 USD |
| 利息支出 | 893.5万 USD | 744.7万 USD | 322.5万 USD | 206.4万 USD | — |
| 折旧和摊销 | 181.6万 USD | 122.5万 USD | 87.7万 USD | 32.6万 USD | 31.2万 USD |
| 营业利润 | −7096.9万 USD | −1.21亿 USD | −1.43亿 USD | −6271.2万 USD | −1215.7万 USD |
| 净利润 | −6641.8万 USD | −1.16亿 USD | −1.36亿 USD | −6209.1万 USD | −1382.7万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$103
上涨空间 35.87%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI9647.38万0.00%2.3万亿 USD0.03%US$381.51-0.11%
iShares Russell 2000 ETFIWM7998.5万0.10%787.4亿 USD0.19%US$278.16-0.28%
Vanguard Extended Market ETFVXF3419.15万0.04%954亿 USD0.05%US$233.77-0.53%
iShares Russell 2000 Growth ETFIWO2828.02万0.20%139.17亿 USD0.24%US$354.07-0.76%
iShares Biotechnology ETFIBB2343.95万0.22%108.2亿 USD0.44%US$204.26-1.08%
Invesco Pharmaceuticals ETFPJP1806.47万3.29%5.48亿 USD0.58%US$123.36+0.39%
Vanguard Russell 2000 ETFVTWO1787.3万0.10%180亿 USD0.06%US$112.37-0.26%
Schwab U.S. Small-Cap ETFSCHA1475.85万0.07%218.24亿 USD0.03%US$32.715-0.23%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBInvesco Pharmaceuticals ETFPJPVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
